Originally posted here:

AIM ImmunoTech Announces Positive Safety Data in First Cohort of Phase 1 Clinical Study Investigating Intranasal Administration of Ampligen as a...

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *


Refresh